Protocol Ledger

NCT03703310 · Phase III · COMPLETED

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Interventional Phase III clinical trial protocol NCT03703310 sponsored by Sol-Gel Technologies in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-19 Enrollment: 174 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03703310
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)174 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03703310
Protocol FieldVerified Registry Value
NCT IdentifierNCT03703310
Consolidated Lead SponsorSol-Gel Technologies
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment174 participants (ACTUAL)
Registered Start Date2019-02-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI